Potent and selective inhibition of gene expression by an antisense heptanucleotide View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-07

AUTHORS

Richard W. Wagner, Mark D. Matteucci, Deborah Grant, Teresa Huang, Brian C. Froehler

ABSTRACT

Factors that govern the specificity of an antisense oligonucleotide (ON) for its target RNA include accessibility of the targeted RNA to ON binding, stability of ON/RNA complexes in cells, and susceptibility of the ON/RNA complex to RNase H cleavage. ON specificity is generally proposed to be dependent on its length. To date, virtually all previous antisense experiments have used 12–25 nt-long ONs. We explored the antisense activity and specificity of short (7 and 8 nt) ONs modified with C-5 propyne pyrimidines and phosphorothioate internucleotide linkages. Gene-selective, mismatch sensitive, and RNase H-dependent inhibition was observed for a heptanucleotide ON. We demonstrated that the flanking sequences of the target RNA are a major determinant of specificity. The use of shorter ONs as antisense agents has the distinct advantage of simplified synthesis. These results may lead to a general, cost-effective solution to the development of antisense ONs as therapeutic agents. More... »

PAGES

840-844

References to SciGraph publications

Journal

TITLE

Nature Biotechnology

ISSUE

7

VOLUME

14

Related Patents

  • Antisense Design
  • Phosphate-Modified Oligonucleotide Analogs With Enhanced Immunostimulatory Activity
  • Diagnosis Of Autism Spectrum Disorders And Its Treatment With An Antagonist Or Inhibitor Of The 5-Ht2c Receptor Signaling Pathway
  • Double-Stranded Oligonucleotides
  • Ige Ch3 Peptide Vaccine
  • Antisense Oligomers Targeting Pcsk9
  • Oligonucleotide Conjugates
  • Herpes Simplex Virus Combined Subunit Vaccines And Methods Of Use Thereof
  • Immunostimulatory Nucleic Acids
  • Oligonucleotide Sequences Complementary To Thioredoxin Or Thioredoxin Reductase Genes And Methods Of Using Same To Modulate Cell Growth
  • Immunogenic Complexes And Methods Relating Thereto
  • Antisense Oligonucleotides For Prevention Of Atherosclerosis And Cardiovascular Infections
  • Immunostimulatory Oligonucleotides
  • Double-Stranded Oligonucleotides
  • Antisense Oligonucleotides For Inhibition Of Microrna-21
  • Antibody Against Hypoxia Proteins
  • Oligonucleotide Compositions With Enhanced Efficiency
  • Antisense Design
  • Oligonucleotide Compositions With Enhanced Efficiency
  • Mitofusin Genes And Their Uses
  • Oligonucleotide Compositions With Enhanced Efficiency
  • Combination Treatment For The Treatment Of Hepatitis C Virus Infection
  • Antisense Design
  • Micrornas
  • Hsv-1 And Hsv-2 Vaccines And Methods Of Use Thereof
  • Hypoxia-Regulated Genes
  • Methods Of Treatment Using Antisense Oligomers And Conjugates Targeting Pcsk9
  • Agent For Stimulating Animal Cell Division
  • Methods Of Use For Hsv-1 And Hsv-2 Vaccines
  • Pharmaceutical Composition Comprising Anti-Mirna Antisense Oligonucleotide
  • For Extending Clinical Utility Of Interferon (Ifn) Alpha In Treatment Of A Variety Of Viral And Proliferative Disorders; Increase Efficacy Of Ifn- Alpha And Reduce Ifn- Alpha Treatment-Related Side Effects
  • Immune Stimulatory Oligonucleotide Analogs Containing Modified Sugar Moieties
  • For Stimulating Immune Activation; For Screening Immunostimulatory Compounds
  • Ige Ch3 Peptide Vaccine
  • Immunomodulatory Polynucleotides And Uses Thereof
  • Double-Stranded Oligonucleotides
  • Micro-Rna Mediated Modulation Of Colony Stimulating Factors
  • Ige Ch3 Peptide Vaccine
  • Antitumor Antisense Sequences Directed Against Ribonucleotide Reductase
  • For Controlling The Tumorigenicity And/Or Metastasis Of Neoplastic Cells; In Patient With Tumor Resistant To A Chemotherapeutic Drug
  • Mitofusin Genes And Their Uses
  • Immunostimulatory Nucleic Acids
  • Micromirs
  • High Potency Sirnas For Reducing The Expression Of Target Genes
  • Diagnosis Of Autism Spectrum Disorders And Its Treatment With An Antagonist Or Inhibitor Of The 5-Ht2c Receptor Signaling Pathway
  • Oligonucleotide Compositions With Enhanced Efficiency
  • Manufacture Of Antisense Oligomers And Conjugates Targeting Pcsk9
  • Pharmaceutical Compositions For Treatment Of Microrna Related Diseases
  • Micromirs
  • Antisense Oligomers Targeting Pcsk9
  • Pharmaceutical Compositions For Treatment Of Microrna Related Diseases
  • Immunostimulatory Oligonucleotides
  • Herpes Simplex Virus Combined Subunit Vaccines And Methods Of Use Thereof
  • Immunostimulatory G, U-Containing Oligoribonucleotides
  • Herpes Simplex Virus Combined Subunit Vaccines And Methods Of Use Thereof
  • Antisense Design
  • Comprising A Negatively Charged Organic Carrier And A Positively Charged Antigen; For Facilitating The Induction Of A Cytotoxic T-Lymphocyte Response To An Antigen
  • Oligonucleotide Compositions With Enhanced Efficiency
  • Hypoxia-Regulated Genes
  • Ige Ch3 Peptide Vaccine
  • Transcriptional Repression Of Sodium-Iodide Symporter In Thyroid Carcinoma
  • Short Oligomer Antagonist Compounds For The Modulation Of Target Mrna
  • Rna Antagonist Compounds For The Inhibition Of Apo-B100 Expression
  • Hsv-1 And Hsv-2 Vaccines And Methods Of Use Thereof
  • Oligonucleoside Compounds And Methods For Inhibiting Tumor Growth, Invasion And Metastasis
  • Short Antisense Compounds With Gapmer Configuration
  • Immunostimulatory G, U-Containing Oligoribonucleotides
  • Nucleotide Sequences Coding Membrane Protein For Use In The Diagnosis, Prevention And Treatment Of Nervous System Disorders
  • Pharmaceutical Compositions For Treatment Of Hcv Patients That Are Poor-Responders To Interferon
  • Hsv-1 And Hsv-2 Vaccines And Methods Of Use Thereof
  • Ige Ch3 Peptide Vaccine
  • Antisense Design
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nbt0796-840

    DOI

    http://dx.doi.org/10.1038/nbt0796-840

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1001313757

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/9631007


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biological Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0604", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Genetics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Base Sequence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Line", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chlorocebus aethiops", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cost-Benefit Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gene Expression Regulation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "HeLa Cells", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nucleic Acid Conformation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oligonucleotides, Antisense", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "RNA", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ribonuclease H", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA", 
              "id": "http://www.grid.ac/institutes/grid.418227.a", 
              "name": [
                "Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wagner", 
            "givenName": "Richard W.", 
            "id": "sg:person.01140546674.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140546674.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA", 
              "id": "http://www.grid.ac/institutes/grid.418227.a", 
              "name": [
                "Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Matteucci", 
            "givenName": "Mark D.", 
            "id": "sg:person.0644301021.08", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644301021.08"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA", 
              "id": "http://www.grid.ac/institutes/grid.418227.a", 
              "name": [
                "Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Grant", 
            "givenName": "Deborah", 
            "id": "sg:person.01360553700.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360553700.04"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA", 
              "id": "http://www.grid.ac/institutes/grid.418227.a", 
              "name": [
                "Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Huang", 
            "givenName": "Teresa", 
            "id": "sg:person.01033032674.10", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033032674.10"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA", 
              "id": "http://www.grid.ac/institutes/grid.418227.a", 
              "name": [
                "Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Froehler", 
            "givenName": "Brian C.", 
            "id": "sg:person.01366552317.67", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366552317.67"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/372333a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031628023", 
              "https://doi.org/10.1038/372333a0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1996-07", 
        "datePublishedReg": "1996-07-01", 
        "description": "Factors that govern the specificity of an antisense oligonucleotide (ON) for its target RNA include accessibility of the targeted RNA to ON binding, stability of ON/RNA complexes in cells, and susceptibility of the ON/RNA complex to RNase H cleavage. ON specificity is generally proposed to be dependent on its length. To date, virtually all previous antisense experiments have used 12\u201325 nt-long ONs. We explored the antisense activity and specificity of short (7 and 8 nt) ONs modified with C-5 propyne pyrimidines and phosphorothioate internucleotide linkages. Gene-selective, mismatch sensitive, and RNase H-dependent inhibition was observed for a heptanucleotide ON. We demonstrated that the flanking sequences of the target RNA are a major determinant of specificity. The use of shorter ONs as antisense agents has the distinct advantage of simplified synthesis. These results may lead to a general, cost-effective solution to the development of antisense ONs as therapeutic agents.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nbt0796-840", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1115214", 
            "issn": [
              "1087-0156", 
              "1546-1696"
            ], 
            "name": "Nature Biotechnology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "14"
          }
        ], 
        "keywords": [
          "simplified synthesis", 
          "H cleavage", 
          "internucleotide linkages", 
          "short oligonucleotides", 
          "antisense agents", 
          "antisense activity", 
          "long oligonucleotides", 
          "RNA complex", 
          "oligonucleotide", 
          "complexes", 
          "target RNA", 
          "synthesis", 
          "distinct advantages", 
          "therapeutic agents", 
          "pyrimidine", 
          "selective inhibition", 
          "cleavage", 
          "stability", 
          "agents", 
          "heptanucleotide", 
          "solution", 
          "binding", 
          "antisense oligonucleotide", 
          "antisense experiments", 
          "linkage", 
          "specificity", 
          "activity", 
          "inhibition", 
          "accessibility", 
          "advantages", 
          "experiments", 
          "length", 
          "cost-effective solution", 
          "cells", 
          "use", 
          "results", 
          "development", 
          "dependent inhibition", 
          "RNA", 
          "sequence", 
          "susceptibility", 
          "mismatch", 
          "date", 
          "factors", 
          "major determinant", 
          "determinants", 
          "gene expression", 
          "expression", 
          "propyne pyrimidines"
        ], 
        "name": "Potent and selective inhibition of gene expression by an antisense heptanucleotide", 
        "pagination": "840-844", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1001313757"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nbt0796-840"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "9631007"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nbt0796-840", 
          "https://app.dimensions.ai/details/publication/pub.1001313757"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T20:48", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_293.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nbt0796-840"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nbt0796-840'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nbt0796-840'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nbt0796-840'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nbt0796-840'


     

    This table displays all metadata directly associated to this object as RDF triples.

    190 TRIPLES      21 PREDICATES      88 URIs      79 LITERALS      19 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nbt0796-840 schema:about N21dbddb77ef64cb69e38d2393a6f115c
    2 N445cdb491c374640a9763c539682f607
    3 N5076caffdef94464aae6f16d5b62b903
    4 N7bb50b0520b14d58a6a7c6a2fe9c6a34
    5 N7f5c753e1d6442689be971e649349d87
    6 N862aff5ec68048ae88a39d45ffe603a4
    7 Na4169b0d2dde43e0aac2997bb1b44ccf
    8 Ncf8b3c6f996e4257b735365316ac6b7e
    9 Nd29c3f8e3dd146a0950143c36987829a
    10 Nd974d05f42f4491db663a3adedfb5416
    11 Nd9d15164de3447a19e91d5bef0e1b573
    12 Neac2df19c7b143ada33120193091ffa7
    13 anzsrc-for:06
    14 anzsrc-for:0604
    15 schema:author N9793582ed065423e849bba3a2bd71d1b
    16 schema:citation sg:pub.10.1038/372333a0
    17 schema:datePublished 1996-07
    18 schema:datePublishedReg 1996-07-01
    19 schema:description Factors that govern the specificity of an antisense oligonucleotide (ON) for its target RNA include accessibility of the targeted RNA to ON binding, stability of ON/RNA complexes in cells, and susceptibility of the ON/RNA complex to RNase H cleavage. ON specificity is generally proposed to be dependent on its length. To date, virtually all previous antisense experiments have used 12–25 nt-long ONs. We explored the antisense activity and specificity of short (7 and 8 nt) ONs modified with C-5 propyne pyrimidines and phosphorothioate internucleotide linkages. Gene-selective, mismatch sensitive, and RNase H-dependent inhibition was observed for a heptanucleotide ON. We demonstrated that the flanking sequences of the target RNA are a major determinant of specificity. The use of shorter ONs as antisense agents has the distinct advantage of simplified synthesis. These results may lead to a general, cost-effective solution to the development of antisense ONs as therapeutic agents.
    20 schema:genre article
    21 schema:isAccessibleForFree false
    22 schema:isPartOf N3835324390b94242a65cafbaf68fd0bc
    23 N41a190f2051e42558d60964df150ffde
    24 sg:journal.1115214
    25 schema:keywords H cleavage
    26 RNA
    27 RNA complex
    28 accessibility
    29 activity
    30 advantages
    31 agents
    32 antisense activity
    33 antisense agents
    34 antisense experiments
    35 antisense oligonucleotide
    36 binding
    37 cells
    38 cleavage
    39 complexes
    40 cost-effective solution
    41 date
    42 dependent inhibition
    43 determinants
    44 development
    45 distinct advantages
    46 experiments
    47 expression
    48 factors
    49 gene expression
    50 heptanucleotide
    51 inhibition
    52 internucleotide linkages
    53 length
    54 linkage
    55 long oligonucleotides
    56 major determinant
    57 mismatch
    58 oligonucleotide
    59 propyne pyrimidines
    60 pyrimidine
    61 results
    62 selective inhibition
    63 sequence
    64 short oligonucleotides
    65 simplified synthesis
    66 solution
    67 specificity
    68 stability
    69 susceptibility
    70 synthesis
    71 target RNA
    72 therapeutic agents
    73 use
    74 schema:name Potent and selective inhibition of gene expression by an antisense heptanucleotide
    75 schema:pagination 840-844
    76 schema:productId N5bf7e540c6f0410fa1bfec0ae70c8e6e
    77 Ndfeba589a91245b1ab207123bbb7da3c
    78 Nfb346cbb37034f5bb9033514af500186
    79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001313757
    80 https://doi.org/10.1038/nbt0796-840
    81 schema:sdDatePublished 2022-11-24T20:48
    82 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    83 schema:sdPublisher N52028b3b019f4874975f4e27f3e55d0a
    84 schema:url https://doi.org/10.1038/nbt0796-840
    85 sgo:license sg:explorer/license/
    86 sgo:sdDataset articles
    87 rdf:type schema:ScholarlyArticle
    88 N21dbddb77ef64cb69e38d2393a6f115c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    89 schema:name HeLa Cells
    90 rdf:type schema:DefinedTerm
    91 N3835324390b94242a65cafbaf68fd0bc schema:volumeNumber 14
    92 rdf:type schema:PublicationVolume
    93 N41a190f2051e42558d60964df150ffde schema:issueNumber 7
    94 rdf:type schema:PublicationIssue
    95 N445cdb491c374640a9763c539682f607 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    96 schema:name Cost-Benefit Analysis
    97 rdf:type schema:DefinedTerm
    98 N5076caffdef94464aae6f16d5b62b903 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    99 schema:name Nucleic Acid Conformation
    100 rdf:type schema:DefinedTerm
    101 N52028b3b019f4874975f4e27f3e55d0a schema:name Springer Nature - SN SciGraph project
    102 rdf:type schema:Organization
    103 N5bf7e540c6f0410fa1bfec0ae70c8e6e schema:name doi
    104 schema:value 10.1038/nbt0796-840
    105 rdf:type schema:PropertyValue
    106 N7bb50b0520b14d58a6a7c6a2fe9c6a34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    107 schema:name RNA
    108 rdf:type schema:DefinedTerm
    109 N7f5c753e1d6442689be971e649349d87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    110 schema:name Ribonuclease H
    111 rdf:type schema:DefinedTerm
    112 N862aff5ec68048ae88a39d45ffe603a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    113 schema:name Chlorocebus aethiops
    114 rdf:type schema:DefinedTerm
    115 N9793582ed065423e849bba3a2bd71d1b rdf:first sg:person.01140546674.47
    116 rdf:rest Nb0fd5f22e52544ce99ab5323eb86e70c
    117 Na1618ea9fb2c4c82b1f185e5971706a8 rdf:first sg:person.01360553700.04
    118 rdf:rest Na78b6daa4df04cb3957645a2f95995cb
    119 Na4169b0d2dde43e0aac2997bb1b44ccf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Gene Expression Regulation
    121 rdf:type schema:DefinedTerm
    122 Na78b6daa4df04cb3957645a2f95995cb rdf:first sg:person.01033032674.10
    123 rdf:rest Ndd32d1233e6243a090088510eb7c83c5
    124 Nb0fd5f22e52544ce99ab5323eb86e70c rdf:first sg:person.0644301021.08
    125 rdf:rest Na1618ea9fb2c4c82b1f185e5971706a8
    126 Ncf8b3c6f996e4257b735365316ac6b7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Animals
    128 rdf:type schema:DefinedTerm
    129 Nd29c3f8e3dd146a0950143c36987829a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    130 schema:name Base Sequence
    131 rdf:type schema:DefinedTerm
    132 Nd974d05f42f4491db663a3adedfb5416 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Cell Line
    134 rdf:type schema:DefinedTerm
    135 Nd9d15164de3447a19e91d5bef0e1b573 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Humans
    137 rdf:type schema:DefinedTerm
    138 Ndd32d1233e6243a090088510eb7c83c5 rdf:first sg:person.01366552317.67
    139 rdf:rest rdf:nil
    140 Ndfeba589a91245b1ab207123bbb7da3c schema:name dimensions_id
    141 schema:value pub.1001313757
    142 rdf:type schema:PropertyValue
    143 Neac2df19c7b143ada33120193091ffa7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Oligonucleotides, Antisense
    145 rdf:type schema:DefinedTerm
    146 Nfb346cbb37034f5bb9033514af500186 schema:name pubmed_id
    147 schema:value 9631007
    148 rdf:type schema:PropertyValue
    149 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    150 schema:name Biological Sciences
    151 rdf:type schema:DefinedTerm
    152 anzsrc-for:0604 schema:inDefinedTermSet anzsrc-for:
    153 schema:name Genetics
    154 rdf:type schema:DefinedTerm
    155 sg:journal.1115214 schema:issn 1087-0156
    156 1546-1696
    157 schema:name Nature Biotechnology
    158 schema:publisher Springer Nature
    159 rdf:type schema:Periodical
    160 sg:person.01033032674.10 schema:affiliation grid-institutes:grid.418227.a
    161 schema:familyName Huang
    162 schema:givenName Teresa
    163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033032674.10
    164 rdf:type schema:Person
    165 sg:person.01140546674.47 schema:affiliation grid-institutes:grid.418227.a
    166 schema:familyName Wagner
    167 schema:givenName Richard W.
    168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140546674.47
    169 rdf:type schema:Person
    170 sg:person.01360553700.04 schema:affiliation grid-institutes:grid.418227.a
    171 schema:familyName Grant
    172 schema:givenName Deborah
    173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360553700.04
    174 rdf:type schema:Person
    175 sg:person.01366552317.67 schema:affiliation grid-institutes:grid.418227.a
    176 schema:familyName Froehler
    177 schema:givenName Brian C.
    178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366552317.67
    179 rdf:type schema:Person
    180 sg:person.0644301021.08 schema:affiliation grid-institutes:grid.418227.a
    181 schema:familyName Matteucci
    182 schema:givenName Mark D.
    183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644301021.08
    184 rdf:type schema:Person
    185 sg:pub.10.1038/372333a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031628023
    186 https://doi.org/10.1038/372333a0
    187 rdf:type schema:CreativeWork
    188 grid-institutes:grid.418227.a schema:alternateName Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA
    189 schema:name Gilead Sciences, 353 Lakeside Dr., 94404, Foster City, CA
    190 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...